Figure 1From: Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS) for all patients. The 2-year PFS & OS rate was 79.3% (95% CI 58.4 ~ 99.6%) and 73.2% (95% CI 52.4 ~ 93.6%).Back to article page